The clearance also applies to an expanded indication in pediatric patients and use in the S1 trajectory. the company said. The implant is designed for sacroiliac fusion and sacropelvic fixation.
In 2022, the iFuse Bedrock Granite system earned its initial clearance. It also has the FDA’s Breakthrough Device Designation and a New Technology Add-on Payment from CMS.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
